December 12, 2024

Innovation Prize 2025 of the German BioRegions – Application Deadline: February 14, 2025

Innovation Prize 2025 of the German BioRegions – Application Deadline: February 14, 2025
Go back

Innovators wanted. APPLY NOW!
WE SUPPORT YOUR INNOVATIVE INVENTION!

The work group of the BioRegions in Germany is the central network of regional initiatives promoting the economic use of modern biotechnologies in Germany. It annually awards the Innovation Prize of the BioRegions in Germany. This year, the work group again recognizes application-oriented ideas with strong implementation potential and showcases them at the German Biotech Days.

What is awarded?

  • The Innovation Prize honors innovative ideas that are patented or have been submitted for patenting.
  • We seek application-oriented ideas with strong implementation potential and high market opportunities.
  • Our aim is to support outstanding innovations that can significantly contribute to the economy and society.

Who can apply?

  • Scientists from universities and non-university institutions
  • Legal entities under public law, such as universities, universities of applied sciences, or patent exploitation agencies
  • Founders of companies that have not yet generated significant revenue and have not transferred substantial company shares to external investors

What do we offer?

  • Invitation for six finalists to the German Biotech Days on April 9 and 10, 2025, in Heidelberg
  • Presentation to an international audience, financiers, and the trade press
  • Three awards, each worth €2,000
  • An audience award worth €2,000

Apply now!

Application Deadline: February 14, 2025.

TO THE APPLICATION
Innopreis_2025_Flyer_EDownload

Our latest News

discover more
Helping children with cancer with flowers

Helping children with cancer with flowers

From April 28 to May 24, you can once again buy and give flower creations throughout Germany for the benefit of children and young people with cancer. With its campaign “Blumen schenken. Hoffnung spenden.” (Give flowers. Spread hope.) the Hopp Children’s Cancer Center Heidelberg (KiTZ) wants to draw attention to the urgently needed research for […]

read more
Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma

Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma

GSK plc (LSE/NYSE: GSK) today announced the authorisation of Blenrep by the Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Blenrep is approved for the treatment of adults with multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) in […]

read more
New regulatory protein of the neuronal cytoskeleton identified

New regulatory protein of the neuronal cytoskeleton identified

The growth and function of nerve cells is based on a lattice-like structure called membrane-associated periodic skeleton (MPS). However, how the organization of the MPS is controlled has not been elucidated until now. A team from the Max Planck Institutes for Medical Research and for Multidisciplinary Sciences has now discovered that it is regulated by […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp